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Abstract
Background: It is estimated that over 40 % of the 218,000 people with chronic hepatitis B (CHB) in Australia in
2011 are undiagnosed. A disproportionate number of those with undiagnosed infection were born in the
Asia-Pacific region. Undiagnosed CHB can lead to ongoing transmission and late diagnosis limits opportunities to
prevent progression to hepatocellular carcinoma (HCC) and cirrhosis.
Strategies are needed to increase testing for hepatitis B virus (HBV) (including culturally and linguistically diverse
communities, Aboriginal and/or Torres Strait Islander (Indigenous) people and people who inject drugs). General
practitioners (GPs) have a vital role in increasing HBV testing and the timely diagnosis CHB. This paper describes the
impact of a GP-based screening intervention to improve CHB diagnosis among priority populations in Melbourne,
Australia.
Methods: A non-randomised, pre-post intervention study was conducted between 2012 and 2013 with three
general practices in Melbourne, Australia. Using clinic electronic health records three priority populations known to
be at increased CHB risk in Australia (1: Asian-born patients or patients of Asian ethnicity living in Australia; 2:
Indigenous people; or 3): people with a history of injecting drugs were identified and their HBV status recorded.
A random sample were then invited to attend their GP for HBV testing and/or vaccination. Baseline and follow-up
electronic data collection identified patients that subsequently had a consultation and HBV screening test and/or
vaccination.
Results: From a total of 33,297 active patients, 2674 (8 %) were identified as a priority population at baseline; 2275
(85.1 %) of these patients had unknown HBV status from which 338 (14.0 %) were randomly sampled. One-fifth
(n = 73, 21.6 %) of sampled patients subsequently had a GP consultation during the study period; only four people
(5.5 %) were subsequently tested for HBV (CHB detected in n = 1) and none were vaccinated against HBV.
Conclusion: CHB infection is an important long-term health issue in Australia and strategies to increase appropriate
and timely testing are required. The study was effective at identifying whether Asian-born patients and patients of
Asian had been tested or vaccinated for HBV; however the intervention was not effective at increasing HBV testing.
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Background
Despite being a leading cause of HCC globally, the
asymptomatic nature of chronic hepatitis B (CHB) infec-
tion has resulted in a large number of undiagnosed cases
[1–3]. The majority of CHB infections are acquired at
birth or during early childhood with between 80 and
90 % of infants infected with hepatitis B virus (HBV) at
birth developing CHB, compared to 30 % of infections
among people aged ≤6 years and 5 % among adults [4,
5].
Current estimates suggest there are 218,000 people
living with CHB in Australia; over half (56 %) born
overseas and one-third (38 %) of this group were born in
the Asia/Pacific region, a region with several countries
with high and intermediate CHB prevalence [3, 6]. Recent
estimates suggest that 44 % of people living with CHB in
Australia are undiagnosed [3]. Only 5 % of people living
with CHB are currently receiving antiviral therapy [7],
representing a minority of the estimated 10–25 % who
would benefit from treatment [8–11]. Undiagnosed CHB
can lead to ongoing transmission, while late diagnosis
limits opportunities to prevent progression to HCC or cir-
rhosis [4]. Further, HCC is the fastest increasing cause of
cancer mortality in Australia, with the annual number of
new cases increasing from 1.8 to 5.2 per 100,000 popula-
tion between 1982 and 2007 [12]. It is imperative that
those living with CHB are diagnosed in an timely manner
as treatment significantly reduces the risk of HCC [13],
and early detection of HCC is associated with improved
5-year survival rates [14].
Australia’s Second National HBV Strategy 2014–2017
(hereafter referred to as the Strategy) includes the target
of increasing the proportion of people living with CHB
that are diagnosed from 56 to 80 % by 2017 [8]. Priority
populations identified in the Strategy include people
from culturally and linguistically diverse backgrounds,
particularly people born in Asia, the Pacific or Sub-
Saharan African background, Indigenous people, and
people who inject drugs (PWID). These groups have
been identified as having reduced access to and use of
health services, including preventative health programs
and cancer screening [3, 15–20]. Key to achieving the
CHB diagnosis target is the collection and recording of
demographic data in health care settings to identify pri-
ority populations; however, recording of ethnicity and/or
country of birth and Indigenous status in general prac-
tice settings is low in Australia [21, 22]. Therefore, strat-
egies are needed to improve identification of priority
populations in general practice and to increase HBV
testing and appropriate follow-up care, including vaccin-
ation or treatment.
This paper presents results of a pilot study conducted
with general practice clinics to identify people at increased
risk of HBV in three priority populations (Asian-born
patients or patients of Asian ethnicity, Indigenous people
or PWID), and increase HBV testing and, where appropri-
ate, HBV vaccination in these populations.
Methods
Study design
A non-randomised, pre-post pilot study was conducted
between December 2012 and April 2013 in three general
practices located in Melbourne, Australia. General prac-
tices were purposively selected in suburbs with a high
proportion of Asian-born residents [23] and with a high
case-load of Asian-born patients. The study included the
implementation of a system to increase identification of
people in high risk populations and a call back system to
increase HBV testing and vaccination where appropriate.
Stakeholders, including non-governmental organisations
working in the areas of cancer prevention and hepatitis
management, GPs and hepatology specialists were en-
gaged during the design of the intervention.
Site selection
The three clinics were located in suburbs with varying
Index of Relative Socio-economic Disadvantage (IRSD)
scores. The IRSD is an index of socio-economic status de-
veloped by the Australian Bureau of Statistics (ABS) based
on the most recent Census (2011) which summarises a
range of information about the economic and social con-
ditions of people and households within a geographic area.
The mean IRSD score is 1000; lower scores indicate rela-
tively greater disadvantage in general whilst higher scores
indicate relative lack of disadvantage generally. In 2011 the
ISDR range across Australia was 588-1191 [24]. Clinic sizes
ranged from small (~2500 active patients) to large (over
20,000 active patients). Two clinics did not charge private
fees in addition to the fee billed through the national health
insurance scheme (“Medicare”, see http://www.humanservi-
ces.gov.au/customer/subjects/medicare-services, Table 1).
Identification of patients from priority population and
sampling
The source population were active patients defined as those
who attended participating clinics within the previous
24 months, aged 18 years and over, and were a member of
one of the three following priority populations: 1) Asian-
born patients or patients of Asian ethnicity living in
Australia; 2) Indigenous people; or 3) people with a history
of injecting drugs (herein referred to as people who inject
drugs, PWID) were identified (see below for these methods).
Asian-born patients or patients of Asian ethnicity liv-
ing in Australia were identified using a United States-
developed electronic name-list predictive of people with
Asian ethnicity [25]. The methods of developing the
name list have been previously described [25, 26]. In
short, a list of 20,000 names was developed in the
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United States from Social Security and Medicare admin-
istration records as a predictive method to identify eth-
nicity from the six major Asian ethnic groups in the
United States, including Chinese (including those from
Hong Kong and Taiwan), Japanese, Filipino, Korean
(North and South), Indian and Vietnamese. The name
list was applied by the GRHANITE™ technology [27] to
determine the eligible Asian ethnicity population within
each practice. The name list has been validated for use
in screening patients for risk of CHB in the Australian
state of Victoria [28] and has been used effectively in the
United States to identify patients to receive electronic
prompts to increase HBV tests [26]. GRHANITE™ tech-
nology interfaced with the clinic’s electronic health rec-
ord (EHR) and applied the name list creating a flag for a
match on first name, surname of both. This flag was ex-
tracted, in addition to other demographic and clinical
details contained within the EHR.
Indigenous people included those that were coded
as Aboriginal, Torres Strait Islander or both in a
clinics EHR. PWID are not routinely identified in
EHRs, and this population was identified through
electronic review of clinical notes from the previous
four years to identify records that suggested a history
of injecting drug use by patients (for example, opioid
substitution therapy). It was not possible to differenti-
ate between current and former injecting drug use
and therefore people with clinical notes indicating
both current and former injecting drug use are
included.
Electronic identification of electronic health record data
extraction software
De-identified data for the eligible study population were
then automatically forwarded to the study secure data
repository. The de-identified data were extracted at the
individual patient level as per the study ethics permitted
with the extraction happening in conjunction with an
opt-out patient consent policy. A unique number map-
ping to the EHR record number was extracted to allow
for re-identification of patients in the intervention arm
by the practice without researchers having any access to
person identifiers.
Intervention
A random sample of those identified as being in a prior-
ity population were generated at each clinic for the
intervention; the number of patients randomly sampled
differed between clinics based on available resources at
each clinic for conducting the intervention. Patients that:
1) matched the name-list for both first name and sur-
name or identified as Indigenous or PWID (the priority
populations); and 2) with no history of HBV testing
within the previous four years or with a testing history
that indicated HBV susceptibility (see Table 1 below),
were sampled. Randomisation was based on the month
of birth of patients in the source population; patients
selected included those born in September, October
and November in all clinics and in the third and lar-
gest clinic, the sample was further refined to include
patients born in even-numbered years only to ensure
a manageable sample size for clinic staff overseeing
the intervention.
The intervention comprised of an invitation to each
member of the sample to attend the clinic for HBV test-
ing or vaccination where there was evidence of HBV sus-
ceptibility. Methods for patient contact differed between
clinics and were selected and implemented by clinic ad-
ministration staff in consultation with the project team.
Clinics 1 and 2 mailed invitation letters to patients and
Clinic 3 undertook a combination of mailed letters and
telephone calls. The invitation letter was in English only
however telephone calls were made by bilingual admin-
istrative staff. Non-respondents were not followed up
(that is, the sample population received one invitation
only) and the majority of invitations were sent between
September and December 2012; in one clinic, the final
invitations were sent on 11 April 2013. Approximately
one-third of the invitations were delivered each month
during the invitation period to ensure a manageable
workload at clinics. The intervention period differed for
patients according to the month of invitation, and ended
on 30 April 2013 for all patients to allow sufficient time
for potential consultation in response to the intervention
(i.e., allowing a minimum of approximately three weeks
and maximum of six months following the intervention
to have a consultation).
Table 1 Description of participating general practice clinics
Clinic 1 Clinic 2 Clinic 3
Number of doctors 5 2 5
Total number of active patients 8959 2424 21,914
Index of Relative Socio-economic
Disadvantage score
1088 1060 908
Public or private billing Medicare payment plus some private fee Bulk billed Medicare payment only
(no private fee)
Bulk billed Medicare payment only
(no private fee)
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Electronic review of EHR and data collection
GRHANITE™ automated data extractions provided both
the pre-intervention baseline and intervention period
follow up study data. Four years of retrospective data
were collected in November 2011 from all clinics; retro-
spective data allowed for review of previous HBV testing
and identification of patients from priority populations.
A second data extract was collected in April 2013 contain-
ing data from November 2011 until April 2013, allowing
comparisons to be made in the pre-intervention and post-
intervention periods.
Information on patients, consultations, requests and
the corresponding results were collated. Demographic
data collected included sex, age at consultation (derived
from date of birth), Indigenous status, country of birth,
flag for name match to list of Asian names (yes/no) and
the patient’s unique ID number (to identify patients eli-
gible for the intervention and monitor the interventions
impact). HBV testing history data collected included if a
test was requested (yes/no), the date of the consultation,
the date the test was conducted (restricted to tests after
1/8/2007) and test result; pathology test reports were
stored as fixed-layout flat document (i.e., PDF) and re-
sults were identified through text mining.
Diagnostic tests for HBV collected in this study include
hepatitis B surface antigen (HBsAg), hepatitis B surface
antibody (anti-HBs) and hepatitis B core antibody (anti-
HBc). Case definitions used to determine HBV infection
and immunity status are presented in Table 2.
Outcome measures
Outcome measures included in this analysis were: 1) the
number of people identified as a priority population that
were previously untested; 2) the number of people identi-
fied as a priority population that were previously untested
and who subsequently had a HBV test; 3) the number of
people identified as a priority population that were previ-
ously untested and who subsequently had a HBV test and
whose HBV test results indicated CHB infection; and 4)
the number of people identified as a priority population
that were previously untested and who subsequently had a
HBV test and whose HBV test results indicated suscepti-
bility and were vaccinated.
Ethical approval
The project received ethical approval from the Royal
Australian College of General Practitioners (RACGP)
National Research and Evaluation Ethics Committee and
an opt-out consent mechanism was implemented at the
practice level.
Results
Description of source population
A total of 33,297 active patients were identified across the
three clinics’ patient management systems at baseline. A
total of 2674 (8 %) of these patients were identified as a
priority population for HBV testing and comprised the
source population for the intervention. Nearly all of the
source population were classified as Asian-born or of
Asian ethnicity (n = 2654, 99.3 %). Eighteen (0.7 %) of the
source population were people who identified as Indigen-
ous and two (0.1 %) were PWID.
The majority of the source population (n = 2275,
85.1 %) had unknown HBV status and 399 (14.9 %) had
known HBV status. Among the 399 patients with known
HBV status, over half were HBV immune (n = 222,
62.2 %), 78 (21.8 %) were susceptible to HBV (i.e., CHB
negative but no evidence of vaccination or natural im-
munity), and 57 (16.0 %) were CHB-negative with insuf-
ficient information to determine immunity status. Ten
percent of the source population was found to have
chronic infection (n = 42, 10.5 %) Table 3).
A total of 2409 (90.1 %) of patients from the source
population were eligible for sampling for the second
phase of the study (that is, patients with unknown HBV
status and patients with known HBV status that were
susceptible to HBV or with unknown immunity status).
Intervention description and results
Three hundred and thirty-eight (14.0 %) of the eligible
source population were randomly sampled for the inter-
vention. Approximately one-third of the sample was
recalled each month; 27.5 % in month 1, 38.8 % in month
2, 33.7 % in month 3. Of the 338 patients that were sent a
recall letter or telephone call, one-fifth (n = 73, 21.6 %)
subsequently had a GP consultation during the study fol-
low up period. Among the 73 that subsequently consulted
a GP in the follow up period, only 4 (5.5 %) were tested
for HBV, one of whom had CHB detected. None of the
Table 2 Case definitions to determine HBV infection and
vaccination status
Infection status
Unknown HBV status No history of HBV
testing




CHB-negative and HBV susceptible






(vaccine-derived immunity or natural immunity)
HBsAg not detected
and Anti-HBs detected




HBsAg hepatitis B surface antigen, anti-HBs hepatitis B surface antibody,
anti-HBc hepatitis B core antibody
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other three patients commenced vaccination for HBV in
the study period (Table 4).
Discussion
CHB infection is a major long-term health issue in
Australia due to the large number of Australians from
culturally and linguistically diverse communities born in
regions with moderate and high CHB prevalence, how-
ever diagnosis rates are unacceptably low. In this study,
we found that electronic review of EHR database was an
efficient and reasonably successful method to identify
patients at increased risk of CHB and determine their
HBV testing history. However, among those identified at
increased risk and who were invited to the clinic for
HBV testing or vaccination, there was a low rate of sub-
sequent consultations and an even lower rate of HBV
testing.
In this study, only 2.5 % of people who were identified
as at-risk of CHB had country of birth recorded (data not
presented in table), and therefore using the name-list
greatly increased the number of at-risk patients identified
than would have been identified if traditional identifiers
were used. Several countries utilise similar electronic
name-based ethnicity classification systems to supplement
Table 3 Description of source population
n %
Description of active patients
Total number of active patients 33,297
Description of source population 2,674 8.0 %
Method of population identification
Patients with Asian ethnicity 2,654 99.3 %
Indigenous people 18 0.7 %
People who inject drugs or with a history of injecting drugs 2 0.1 %
HBV infection and immunity status of source population
Patients with unknown HBV status 2,274 85.1 %
Patients with known HBV status 399 14.9 %
Chronic HBV detected (% among patients with known HBV status, n = 399) 42 (10.5 %)
Chronic HBV not detected (% among patients with known HBV status, n = 399) 357 (89.5 %)
Susceptible to HBV (% among patients with no evidence of chronic HBV, n = 357) 78 (21.8 %)
Immune to HBV (% among patients with no evidence of chronic HBV, n = 357) 222 (62.2 %)
Unknown immunity status (% among patients with no evidence of chronic HBV, n = 357) 57 (16.0 %)
Eligible patients in source population (Patients with unknown HBV status and Patients with known HBV status that were susceptible
to HBV or with unknown immunity status)
2,409 90.1 %
Table 4 Intervention description and results
n %
Number of patients sampled for intervention (% of source population) 338 (14.0 %)
Sep-11 93 27.5 %
Oct-11 131 38.8 %
Nov-11 114 33.7 %
Reason for intervention invitation
HBV vaccination (% of patients sampled) 78 23.1 %
HBV testing (% of patients sampled) 260 76.9 %
Intervention impact
Number of patients recalled that subsequently consulted a GP during the intervention period 73 21.6 %
Number of patients that had a consultation and tested for HBV (% of patients that subsequently had a GP consultation) 4 (5.5 %)
Chronic HBV detected (% of patients that subsequently had a GP consultation and were tested for HBV) 1 (25.0 %)
Chronic HBV not detected (% of patients that subsequently had a GP consultation and were tested for HBV) 3 (75.0 %)
Number of patients that had a consultation and were vaccinated against HBV (% of patients that subsequently had a GP
consultation)
0 (0 %)
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population health datasets when ethnicity data is not col-
lected or incomplete. For example, Nam Pehchan and
OnoMAP software have been used extensively in health
research internationally and show utility in identifying
people from Asian backgrounds [29–32]. No name-based
ethnicity classification system is perfect however, and al-
ternative strategies to improve the collection of informa-
tion on cultural and/or ethnic background should be
considered in general practice. For example, the recording
of other cultural backgrounds of patients (including coun-
try of birth and language) is currently a discretionary data
item in to the RACGP Standards for General Practice
[33], however it may increase data completeness if this
were revised to ensure it is a mandatory item. In addition,
incentives to increase data completeness could be consid-
ered. In the United Kingdom, incentivisation of ethnicity
(under the Quality and Outcomes Framework) improved
completeness of ethnicity data for newly registered pa-
tients in general practices from 30 % to 80 % [34].
Whilst it was efficient to extract routinely collected data
such as Indigenous status, the use of these data also relies
on high levels of data completeness. Measuring the real
burden of disease in Indigenous people is complicated by
under-identification of in administrative health data col-
lections, including general practice [35, 36]. Recording In-
digenous status is a mandatory data item for accreditation
purposes in the RACGP Standards [33] however data
completeness in general practice is low, with around 60 %
of Indigenous people having their status recorded [21].
Data completeness in this study was lower (around 45 %)
and very few Indigenous people were subsequently identi-
fied. The prevalence of CHB in Indigenous people is
higher than non-Indigenous people, and is estimated to be
around 4 % [37]. Therefore, considerable efforts are re-
quired to increase data completeness to an acceptable
level in general practice in Australia to ensure those living
with CHB are identified. The indigenous Māori ethnic
group in New Zealand, who have an estimated HBsAg
prevalence of 5.6 % [38], had similarly low levels of ethni-
city data completeness in the early 2000s; the implementa-
tion of a population-based funding model adjusted for
ethnicity led to higher completeness rates of ethnicity in
general practice datasets [39, 40]. An incentivised program
also exists in Australia - the Indigenous Health Incentive,
operating through the Practice Incentives Program and
implemented through Medicare Australia [41]. The incen-
tives offered through the Indigenous Health Incentive dif-
fer from the New Zealand model in that practices receive
individualised payments for chronic disease management
rather a population approach based on a whole-of-
practice profile that requires higher levels of data com-
pleteness; a population approach to incentivisation may
improve the identification of Indigenous people in general
practice datasets.
There is currently not an efficient method to identify
PWID in EHRs and patient notes were the main source of
information used to identify these patients. This has con-
siderable ethical implications and has the potential to
introduce bias to the classification of patients by priority
grouping. Further examination of efficient and ethical ap-
proaches to identifying PWID in clinical datasets is war-
ranted, however it should be noted mainstream general
practices may not be the most appropriate place to iden-
tify PWID for HBV care models. Issues such as stigma
and expertise and level of comfort of providers in main-
stream services may hinder service delivery to PWID and
integrated care models that comprehensively address the
complex range of health and social welfare needs of PWID
are more appropriate services to provide testing and
vaccination [42–44].
Identifying people at increased risk is important and
our intervention was successful at this. However if we
are to reach the Strategy’s target of that 80 % of people
living with CHB that are diagnosed by 2017 it is vital
that those identified as being at increased risk are tested
to confirm their HBV status and then receive appropri-
ate follow up. For those at risk of HBV, appropriate fol-
low up includes HBV vaccination whilst for those
diagnosed with CHB it includes regular follow up. Our
findings reveal an extremely low baseline testing rate,
with approximately 10 % of patients identified as at in-
creased risk of CHB having had a test for CHB at the
participating clinic in the previous four years. A low test-
ing rate is likely to have fed into a low diagnosis rate.
Based on estimates of CHB prevalence among people
born in Asia/Pacific (3.55 %) [3], at least 94 people at-
tending the participating clinics are likely to be living
with CHB yet only 41 cases of CHB were identified
through the initial data extraction and one additional
case was identified in this study. A proportion of those
remaining undiagnosed pose ongoing risks in relation to
HBV transmission and CHB related morbidity and
mortality.
Our intervention of sending invitations to those identi-
fied as at risk failed to increase consultation rates above
the average attendance for people in this age range [45],
and failed to increase HBV testing and vaccination in
priority patients who attended the clinic in the study fol-
low up period. Among those that did have a consult-
ation, around 5 % subsequently had a HBV test. The
reason why a HBV test was not requested in the
remaining 95 % of consultations is not known, however
it is possible that GPs were not aware of the patients
identified risk of CHB and that consultations addressed
other health concerns. It should be noted that GPs were
not prompted (electronically or otherwise) at this visit to
offer HBV testing and therefore interventions that oper-
ate at a clinic administration-patient level, without
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consultation level prompting or involvement of GPs,
may offer limited utility.
In addition to low levels of testing in those that
returned to the clinics, feedback from practice managers
who oversaw the intervention implementation empha-
sised the resource intensity of the manual invitation
process (i.e., generating the recall list and generating in-
vitation letters or making telephone calls) suggesting
such a system would not be sustainable even if testing
had been higher. This highlights the need to investigate
alternative efficient and sustainable models to prompt
HBV testing among priority populations such as point-
of-care electronic health reminders (that is, electronic
reminders delivered during patient consultations) or re-
minders delivered prior to consultations. The use of
electronic health reminders for preventive care in gen-
eral practice has increased in recent years, including
clinician reminders delivered before and after consulta-
tions (33). Systematic reviews of electronic health re-
minders have reported inconclusive results on their
impact to increase preventative care measures [46, 47],
however it is suggested that reminders delivered during
consultations may be more successful compared to re-
minders delivered before consultations [47]. To date
only one study has evaluated the impact of electronic
health reminders to prompt HBV testing; a small rando-
mised controlled trial in the United States determined
the effectiveness of electronic reminders (emailed to
clinicians 24 h before a patients’ scheduled appointment)
to increase ordering of HBV tests among adults with
Chinese and Vietnamese surnames (using the same
name list used in this study). The trial was highly effective,
with HBV tests being ordered for 41 % of consultations in
the group that received an electronic reminder compared
to 1 % of consultations in the control group [26].
Several limitations in this pilot intervention are noted.
First, the study was a pilot and thus minimum sample
sizes to observe the impact of the intervention were not
calculated. Second, clinics were selected for their close
contact with the target population, and therefore are not
representative of broader general practice in Victoria.
Third, the screening tool only comprised of names from
six major Asian ethic groups and is not representative of
ethnic or geographic areas with moderate and high CHB
prevalence globally. In the Australian context, it would
be greatly beneficial if names indicative of Pacific and
African origin were also included. Fourth, the definition
of active patients was broad and included patients with
one consultation only at the participating clinic in the
preceding four years before the intervention; these
patients may have received the invitation but presented
to a different clinic or not received the recall at all due
to out of date personal information. Finally, the period
of follow up after invitation to the study may have
missed additional members of the target population who
attended a clinic after the intervention follow up period.
Conclusion
CHB is an increasingly important long-term health issue
in Australia and many other countries. This intervention
was effective at identifying Asian-born patients and pa-
tients of Asian ethnicity who may be at increased risk of
CHB but was not effective in increasing HBV testing in
this priority population. Further research is recom-
mended to identify efficient and sustainable strategies to
increase HBV testing in priority populations, such as the
use of within-consultation electronic health reminders.
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